TGFB1 and neoplasm: Thus, antibodies that neutralize TGF-β1 or block TGF-β1 activation from GARP:TGF-β1 complexes do not display anti-tumor activity when administered as monotherapies in CT26 tumor-bearing mice (Fig. 2b).